Login
Navigate Fool.com
Will BTX beat
the market?

BioTime, Inc.

NYSEMKT: BTX

Community Rating: 1 Star: Ominous

2.78 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.73
Previous Close $2.78
Daily Range $2.68 - $2.87
52-Week Range $2.59 - $4.82
Market Cap $193.5M
P/E Ratio -3.37
Dividend (Yield) $0.00 (0.0%)
Volume 107,077
Average Daily Volume 248,052
Current FY EPS $0.00

How do you think BTX
will perform against the market?

Top BTX Bull/Bear Pitches

 

whatsupprahalad (0)
Submitted October 20, 2009

Biotime has Dr Michael West as its CEO Biotime primary growth machine is going to be Stem cell related products and assays. Stem cell industry has the following major issues. 1. Purity. 2. Scalabili … More

1 Replies Reply Report this Post
 

Beorn10 (< 20)
Submitted October 12, 2010

A California company with 17 employees and a net profit margin of minus 346% in the second quarter of 2010 (Google Finance).

0 Replies Reply Report this Post

News & Commentary Rss Feed

Is Geron Finally Onto Something?

Here's why biotech Geron is a prime buyout target.

Stocks: Insiders Buy at Titan International, Cytokinetics, and BioTime

Plus, a purchase at Clearfield.

Insiders Buy Shares at BioTime, TechTarget, and Accelrys

OFG Bancorp also sees a purchase.

3 Reasons Behind Geron's Rebound

Let’s take a look at three reasons Geron bounced back more than 200% in 2013, and how its industry peers -- Celgene, Novartis, and Incyte -- have been affected.

2 Reasons Behind Geron's Rebound

Why has Geron soared 200% in 2013? Let's look at this biotech's performance and its future.

BioTime’s Subsidiary OncoCyte Corporation and The Wistar Institute To Collaboratively Develop Cancer

BioTime Announces Additional Products in Development Based on HyStem® Technology

Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell

BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications o

BioTime Receives Approval to Begin Human Clinical Trials of Renevia

See More BTX News...

Sector

Healthcare

Industry

Drugs

BioTime, Inc. (BTX) Description

BioTime Inc. is engaged in the business of developing blood plasma volume expanders and related products and stem cell related products and technology for diagnostic therapeutic and research use. Website: http://www.biotimeinc.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks